# A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

> **NCT02137382** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 41 (actual)

## Conditions studied

- Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

## Interventions

- **DRUG:** Creon®
- **DRUG:** Creon N

## Key facts

- **NCT ID:** NCT02137382
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2016-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02137382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02137382, "A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02137382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*